Boehringer Ingelheim and Invetx collaborates to advance monoclonal antibody biotherapeutics in animal health


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Latest pharma news update

Boehringer Ingelheim, a global leader in animal health, and Invetx, a Boston-based pioneer in protein-based therapeutics for animal health, announced that they have entered into a collaboration agreement to develop novel, species-specific monoclonal antibody biotherapeutics targeting a wide range of diseases in the veterinary species, initially focused on dogs and cats.

For each selected disease target, Invetx will apply its unique platform to the discovery and optimization of best-in-class candidates and Boehringer Ingelheim will advance these therapies through clinical and regulatory development to bring them to market. Terms of the agreement were not disclosed.

“This partnership is a prime example of Boehringer Ingelheim’s commitment to addressing unmet needs in the rapidly growing animal health market,” shared Eric Haaksma, Head of Global Innovation, Animal Health at Boehringer Ingelheim. “We were drawn to working with Invetx because of the company’s cutting-edge discovery platform, optimization technologies and antibody expertise. Together, we will leverage innovation to discover breakthrough scientific advancements to improve animal health.”

Today, monoclonal antibodies are currently used in the treatment of many human diseases. The therapy is a form of immunotherapy that uses monoclonal antibodies (mAbs) to bind nonspecifically to certain cells or proteins, mimicking the body’s own natural response to attack those cells. Leveraging the technology in animal health creates the great potential to address unmet needs.

Invetx’s fully integrated platform encompassing discovery, product development and commercial manufacturing sets a new standard for veterinary biotherapeutics. By leveraging validated technologies in human biotech and optimizing them for veterinary application, Invetx can generate differentiated antibodies against a wide range of targets to treat a variety of chronic and serious diseases in animals.

“We are thrilled to partner with global animal health leader Boehringer Ingelheim, using our unique discovery platform to deliver fully species-specific, optimized and half-life extended biotherapeutics,” said Juergen Horn, PhD, Chief Executive Officer, Invetx. “These programs will complement our own proprietary portfolio and strengthen our position as a leader in creating novel, transformative and best-in-class therapies for veterinary patients.”

Tags : #Boeringer #Invetx #MonoclonalAntibody #Biotherapy

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026